A Phase 2/3 interventional study of etrasimod and Placebo in Atopic Dermatitis, Atopic Dermatitis, Unspecified and Eczema, sponsored by Pfizer. Terminated at 74 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-08.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.
Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 33rd largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2023, is the only one in phase 2/3, and was the 42nd registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
Pfizer · Sites in United States
Ages 12+
Pfizer · Sites in United States, China, Hungary and 4 more countries
Ages 2–11
Pfizer · Sites in United States, Bulgaria, Canada and 6 more countries
Ages 18–64
By country, each count listing its studies:
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 15 · Phase 3 18 · Phase 4 2
First in 2009; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is below the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 121 across the 47 interventional studies, 150 across the 9 observational. Of the 43 that completed or were terminated, 34 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Dermatitis, Atopic by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06899204PfizerReal World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. | 2027-02-15 |
| NCT06564389PfizerFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients | 2027-06-02 |
| NCT07887867PfizerA Study to Learn About the Study Medicine Abrocitinib in People With Severe Atopic Dermatitis Who Have Switched From Other Therapies | 2027-10-01 |
| NCT05391061PfizerA Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis | 2027-11-22 |
Add all 4 to your calendar (.ics) → With an account.
Among the 58 studies in Dermatitis, Atopic by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the safety and effects of the study medicine called etrasimod for the possible treatment of atopic dermatitis (AD), also called eczema, in adults who have already tried AD treatments taken by mouth or by injection that work all over the body. These adults can have moderate to severe AD.
This study is seeking participants who:
This is a 2-part study that is only selecting about 60 participants for Part 1 as of now. In Part 1, half of the participants will receive etrasimod, a pill to be taken by mouth once daily. The other half will receive a placebo, a pill that looks like etrasimod but has no medicine also taken by mouth once daily. No one will know what treatment the participant is taking. The Sponsor will compare participant experiences of those taking etrasimod to those taking placebo for 16 weeks. This will help determine if the study medicine is safe and effective. After the first 16 weeks, some participants may continue the study knowing they are taking etrasimod for an additional 52 weeks.
Those participating for just the first 16-weeks, will need to visit the study clinic at least 6 times during the study (about every 4 weeks), and will have to come for 2 safety follow up visits at 2nd and 4th week after the last dose of study medicine. People who want to and can continue for an additional 52 weeks will need to visit the study clinic for at least 6 more visits making 12 total visits over 68 weeks followed by 2 safety follow up visits at the 2nd and 4th week after the last dose of study medicine.
In Part 2 of the study, around 340 more participants will be participating. Everyone will receive etrasimod pills once daily for 52 weeks. Participants will need to go to the study clinic at least 9 times after which they will have to go for 2 more safety follow up visits at the 2nd and 4th weeks after the last dose of study medicine.
At every study visit in Part 1 and Part 2, the focus will be on signs and symptoms of AD (like lesions, itch, and pain) as well as general health and overall side effects. Blood samples and vital signs will be taken at every visit. Due to the way the study medicine works, the in-study clinic visit will last at least 4 hours on Day 1 (Part 1 and Part 2) and Week 16 (Part 1).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet the following key inclusion criteria to be eligible for enrollment into the study:
2 Chronic AD (also known as atopic eczema) that was diagnosed at least 1 year prior to Screening and meets Hanifin and Rajka criteria at screening).1 3. Moderate to severe AD:
Eczema Area and Severity Index (EASI) ≥16 at screening and baseline (Day 1) 4. A participant who has failed a prior systemic therapy for AD, ie, , moderate-to-severe AD that is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
Presence of confounding factors:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 mg, oral tablet, once daily
Drug: etrasimod
Oral sham comparator
Drug: Placebo
PART 1 Double Blind one 2 mg tablet once daily for up to 16 weeks PART 1 Open Label Extension one 2 mg tablet once daily for an additional 52 weeks PART 2 Open Label one 2 mg tablet once daily for up 52 weeks
Also known as: APD334, PF-07915503
PART 1 DOUBLE BLIND Placebo - one table daily for up to 16 weeks
Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16
IGA measured AD severity, based on a 5-point scale (0-4); 0= AD is clear, 1= AD is almost clear, 2= mild AD, 3= moderate AD and 4= severe AD. IGA response was defined as participants achieving IGA 0 (clear) or 1 (almost clear) and a reduction of \>=2 points from baseline.
Time frame: DB Period: Week 16
Part 1, DB Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All Causality)
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment
Part 1, DB Period: Number of Participants With TEAEs (All Causality) Leading to Study Treatment Discontinuation
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment
Part 1, DB Period: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (All Causality)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medical events judged by investigator.
Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment
Part 1, DB Period: Number of Participants With Treatment Emergent AEs of Special Interest (AESIs) (All Causality)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. AESIs included here were cardiovascular events (i.e., bradycardia, Atrioventricular (AV) conduction delay, and hypertension); macular edema, pulmonary events (airflow obstruction or decreased gas exchange); infections (severe infections, opportunistic infections \[including progressive multifocal leukoencephalopathy (PML)\], Herpes simplex and Herpes zoster); liver injury (liver transaminase elevation and bilirubin elevation); posterior reversible encephalopathy syndrome (PRES) and malignancies.
Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment
Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities
Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.
Time frame: DB Period: From first dose of study drug up to 16 Weeks of treatment
Part 1, DB Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks
Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF), and QRS complex. Number of participants with non-zero ECG abnormalities and AV blocks are reported in this outcome measure.
Time frame: DB Period: Pre-dose and 4 hours (hrs) post-dose on Day 1/Week 0; Pre-dose and 4 hrs post-dose on Day 113/Week 16
Part 1, DB Period: Number of Participants With Markedly Abnormal Vital Sign
Vital signs evaluation included systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate. Number of participants with non-zero vital signs abnormalities are reported in this outcome measure.
Time frame: DB Period: Pre-dose and 1, 2, 3, 4 hours (hrs) post-dose on Day 1/Week 0; Day 29/Week 4; Day 57/Week 8; Day 85/Week 12; Pre-dose and 1, 2, 3, 4, 5 and 6 hrs post-dose on Day 113/Week 16
Part 1, OLE Period: Number of Participants With TEAEs (All Causality)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Part 1, OLE Period: Number of Participants With Treatment Emergent AEs (All Causality) Leading to Study Treatment Discontinuation
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Part 1, OLE Period: Number of Participants With Treatment Emergent SAEs (All Causality)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medical events judged by investigator.
Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Part 1, OLE Period: Number of Participants With Treatment Emergent AESIs (All Causality)
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. AESIs included here were cardiovascular events (i.e., bradycardia, AV conduction delay, and hypertension); macular edema, pulmonary events (airflow obstruction or decreased gas exchange); infections (severe infections, opportunistic infections \[including PML\], Herpes simplex and Herpes zoster); liver injury (liver transaminase elevation and/or bilirubin elevation); PRES and malignancies.
Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Part 1, OLE Period: Number of Participants With Laboratory Test Abnormalities
Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.
Time frame: OLE Period: First dose of study drug in OLE period up to 4 weeks after last dose in OLE period (up to maximum of 56 Weeks)
Part 1, OLE Period: Number of Participants With Markedly Abnormal 12-Lead Electrocardiogram Measurements and AV Blocks
Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTcF, and QRS complex. Number of participants with non-zero ECG abnormalities and AV blocks are reported in this outcome measure.
Time frame: OLE Period: Day 169/Week 24
Part 1, OLE Period: Number of Participants With Markedly Abnormal Vital Sign
Vital signs evaluation included SBP, DBP, pulse rate. Number of participants with non-zero vital signs abnormalities are reported in this outcome measure.
Time frame: OLE Period: Day 141/Week 20; Day 169/Week 24; Day 281/Week 40; Follow Up 1; Follow Up 2
Part 1, DB Period: Percentage of Participants Who Achieved >=75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) at Week 16
EASI-75 response was defined as a 75% reduction or greater in EASI score from Baseline to Week 16. EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.
Time frame: DB Period: Week 16
Part 1, DB Period: Percent Change From Baseline in EASI Score at Week 16
EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.
Time frame: DB Period: Baseline, Week 16
The study had 2 parts: Part 1 and Part 2. Part 2 was never initiated; hence no results are reported for it. All results are pertaining to Part 1 in the record. Part 1 of the study had 16-week double-blind (DB) treatment period and then 52-week part 1 open label extension (OLE) treatment period.
| Milestone | DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | DB Placebo Then OLE Etrasimod 2 mg |
|---|---|---|
| Started | 30 | 28 |
| Completed | 27 | 25 |
| Not completed | 3 | 3 |
| Withdrew: Withdrawal by subject | 1 | 2 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
| Milestone | DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | DB Placebo Then OLE Etrasimod 2 mg |
|---|---|---|
| Started | 27 | 24 |
| Completed | 0 | 0 |
| Not completed | 27 | 24 |
| Withdrew: Study terminated by sponsor | 25 | 19 |
| Withdrew: Withdrawal by subject | 2 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 |
IGA measured AD severity, based on a 5-point scale (0-4); 0= AD is clear, 1= AD is almost clear, 2= mild AD, 3= moderate AD and 4= severe AD. IGA response was defined as participants achieving IGA 0 (clear) or 1 (almost clear) and a reduction of \>=2 points from baseline.
| Percentage of Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Part 1, DB Period: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response at Week 16 | 3.3 (3.28 to —) | 7.1 (4.87 to —) |
EASI-75 response was defined as a 75% reduction or greater in EASI score from Baseline to Week 16. EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.
| Percentage of Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Part 1, DB Period: Percentage of Participants Who Achieved >=75% Reduction From Baseline in Eczema Area and Severity Index (EASI) Score (EASI-75) at Week 16 | 23.3 (7.72 to —) | 14.3 (6.61 to —) |
EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs.
| Percent change | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Part 1, DB Period: Percent Change From Baseline in EASI Score at Week 16 | -53.87 ± 9.007 | -24.65 ± 9.533 |
An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Part 1, DB Period: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (All Causality) | 16 | 8 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Part 1, DB Period: Number of Participants With TEAEs (All Causality) Leading to Study Treatment Discontinuation | 1 | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medical events judged by investigator.
| Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Part 1, DB Period: Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) (All Causality) | 0 | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. AESIs included here were cardiovascular events (i.e., bradycardia, Atrioventricular (AV) conduction delay, and hypertension); macular edema, pulmonary events (airflow obstruction or decreased gas exchange); infections (severe infections, opportunistic infections \[including progressive multifocal leukoencephalopathy (PML)\], Herpes simplex and Herpes zoster); liver injury (liver transaminase elevation and bilirubin elevation); posterior reversible encephalopathy syndrome (PRES) and malignancies.
| Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Part 1, DB Period: Number of Participants With Treatment Emergent AEs of Special Interest (AESIs) (All Causality) | 2 | 1 |
Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.
| Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities | 22 | 13 |
Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTc corrected using Fridericia's formula (QTcF), and QRS complex. Number of participants with non-zero ECG abnormalities and AV blocks are reported in this outcome measure.
| Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Pre-dose/Day 1: AV conduction: First-degree AV Block | 1 | 0 |
| 4 hrs post-dose/Day 1: QTCF (msec), single beat:>= 450 (male) or >= 470 (female) | 1 | 0 |
| 4 hrs post-dose/Day 1: Change From Baseline (CFB) in QT: >30 msec increase | 9 | 0 |
| 4 hrs post-dose/Day 1: AV conduction: First degree AV Block | 3 | 0 |
| Pre-dose/Week 16: CFB in QT: >30 msec increase | 1 | 0 |
| Pre-dose/Week 16: CFB in QT: >60 msec increase | 1 | 0 |
| Pre-dose/Week 16: CFB in QTcF: >30 msec increase | 2 | 0 |
| 4 hrs post-dose/Week 16: CFB in QTcF: >30 msec increase | 2 | 0 |
| 4 hrs post-dose/Week 16: CFB in QT: >30 msec increase | 2 | 0 |
| 4 hrs post-dose/Week 16: AV conduction: First degree AV Block | 2 | 0 |
Vital signs evaluation included systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse rate. Number of participants with non-zero vital signs abnormalities are reported in this outcome measure.
| Participants | DB Period: Etrasimod 2 mg | DB Period: Placebo |
|---|---|---|
| Pre-dose/Day 1: DBP >90 mmHg | 0 | 1 |
| Pre-dose/Day 1: Pulse rate: <60 bpm | 1 | 3 |
| Pre-dose/Day 1: Pulse rate >100 bpm | 1 | 0 |
| 1 hr post-dose/Day 1: SBP: Change >=30 mmHg decrease | 0 | 1 |
| 1 hr post-dose/Day 1: DBP >90 mmHg | 2 | 2 |
| 1 hr post-dose/Day 1: Pulse rate: <50 bpm | 1 | 0 |
| 1 hr post-dose/Day 1: Pulse rate: <60 bpm | 7 | 3 |
| 2 hrs post-dose/Day 1: SBP: >150 mmHg | 0 | 2 |
| 2 hrs post-dose/Day 1: DBP >90 mmHg | 0 | 1 |
| 2 hrs post-dose/Day 1: Pulse rate: <60 bpm | 12 | 5 |
| 3 hrs post-dose/Day 1:SBP >150 mmHg | 0 | 1 |
| 3 hrs post-dose/Day 1: SBP: Change>=30 mmHg decrease | 1 | 0 |
| 3 hrs post-dose/Day 1: DBP:>90 mmHg | 0 | 1 |
| 3 hrs post-dose/Day 1: DBP: Change>=20 mmHg decrease | 2 | 0 |
| 3 hrs post-dose/Day 1: Pulse rate: <60 bpm | 11 | 6 |
| 4 hrs post-dose/Day 1: DBP: >90 mmHg | 1 | 1 |
| 4 hrs post-dose/Day 1: Pulse rate: <60 bpm | 10 | 5 |
| 4 hrs post-dose/Day 1: Pulse rate: >100 bpm | 1 | 0 |
| Week 4: DBP:>90 mmHg | 2 | 3 |
| Week 4: Pulse rate: <60 bpm | 2 | 1 |
| Week 4: Pulse rate: >100 bpm | 1 | 0 |
| Week 8: SBP: >150 mmHg | 0 | 1 |
| Week 8: DBP:>90 mmHg | 3 | 3 |
| Week 8: DBP: Change >=20 mmHg decrease | 0 | 1 |
| Week 8: Pulse rate: <60 bpm | 3 | 1 |
| Week 12: SBP: >150 mmHg | 0 | 1 |
| Week 12: DBP:>90 mmHg | 1 | 3 |
| Week 12: Pulse rate: <60 bpm | 1 | 0 |
| Week 12: Pulse rate: >100 bpm | 0 | 2 |
| Pre-dose/Week 16: SBP: >150 mmHg | 0 | 1 |
| Pre-dose/Week 16: DBP: >90 mmHg | 2 | 0 |
| Pre-dose/Week 16: Pulse rate: <60 bpm | 2 | 2 |
| 1 hr post dose/Week 16: SBP: >150 mmHg | 0 | 1 |
| 1 hr post-dose/Week 16: SBP: Change >=30 mmHg decrease | 0 | 1 |
| 1 hr post dose/Week 16: DBP: >90 mmHg | 2 | 1 |
| 1 hr post dose/Week 16: Pulse rate: <50 bpm | 1 | 1 |
| 1 hr post dose/Week 16: Pulse rate: <60 bpm | 3 | 4 |
| 2 hrs post dose/Week 16: SBP: >150 mmHg | 0 | 1 |
| 2 hrs post-dose/Week 16: SBP: Change >=30 mmHg decrease | 0 | 2 |
| 2 hrs post dose/Week 16: DBP: >90 mmHg | 2 | 2 |
| 2 hrs post dose/Week 16: Pulse rate: <50 bpm | 0 | 1 |
| 2 hrs post dose/Week 16: Pulse rate: <60 bpm | 3 | 10 |
| 3 hrs post dose/Week 16:DBP: >90 mmHg | 2 | 0 |
| 3 hrs post dose/Week 16: Pulse rate: <50 bpm | 0 | 1 |
| 3 hrs post dose/Week 16: Pulse rate: <60 bpm | 3 | 9 |
| 4 hrs post dose/Week 16: SBP: >150 mmHg | 0 | 1 |
| 4 hrs post dose/Week 16: DBP:>90 mmHg | 2 | 0 |
| 4 hrs post-dose/Week 16: DBP: Change >=20 mmHg decrease | 0 | 1 |
| 4 hrs post dose/Week 16: Pulse rate: <50 bpm | 0 | 1 |
| 4 hrs post dose/Week 16: Pulse rate:<60 bpm | 1 | 6 |
| 5 hrs post dose/Week 16:Pulse rate:<50 bpm | 0 | 1 |
| 5 hrs post dose/Week 16:Pulse rate:<60 bpm | 0 | 1 |
| 6 hrs post dose/Week 16:Pulse rate:<50 bpm | 0 | 1 |
| 6 hrs post dose/Week 16: Pulse rate:<60 bpm | 0 | 1 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) |
|---|---|---|
| Part 1, OLE Period: Number of Participants With TEAEs (All Causality) | 9 | 5 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) |
|---|---|---|
| Part 1, OLE Period: Number of Participants With Treatment Emergent AEs (All Causality) Leading to Study Treatment Discontinuation | 0 | 1 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life-threatening experience (immediate risk of death); new or prolonged inpatient hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other medical events judged by investigator.
| Participants | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) |
|---|---|---|
| Part 1, OLE Period: Number of Participants With Treatment Emergent SAEs (All Causality) | 1 | 0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Treatment-emergent are events between first dose of study drug and up to last dose that were absent before treatment or that worsened relative to pretreatment state. AESIs included here were cardiovascular events (i.e., bradycardia, AV conduction delay, and hypertension); macular edema, pulmonary events (airflow obstruction or decreased gas exchange); infections (severe infections, opportunistic infections \[including PML\], Herpes simplex and Herpes zoster); liver injury (liver transaminase elevation and/or bilirubin elevation); PRES and malignancies.
| Participants | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) |
|---|---|---|
| Part 1, OLE Period: Number of Participants With Treatment Emergent AESIs (All Causality) | 1 | 0 |
Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.
| Participants | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) |
|---|---|---|
| Part 1, OLE Period: Number of Participants With Laboratory Test Abnormalities | 20 | 18 |
Standard 12-lead ECGs utilizing limb leads were used to measure PR interval, QT interval, QTcF, and QRS complex. Number of participants with non-zero ECG abnormalities and AV blocks are reported in this outcome measure.
| Participants | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) |
|---|---|---|
| Week 24: QTCF (msec), single beat:>= 450 (male) or >= 470 (female) | 1 | 0 |
| Week 24: CFB in QTcF: >30 sec increase | 1 | 0 |
| Week 24: CFB in QT: >30 msec increase | 2 | 0 |
| Week 24: CFB in QT: >60 msec increase | 1 | 0 |
Vital signs evaluation included SBP, DBP, pulse rate. Number of participants with non-zero vital signs abnormalities are reported in this outcome measure.
| Participants | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) |
|---|---|---|
| Week 20: SBP: >150 mmHg | 1 | 1 |
| Week 20: SBP: Change:>=30 mmHg decrease | 0 | 1 |
| Week 20: DBP: >90 mmHg | 2 | 1 |
| Week 20: Pulse rate: <60 bpm | 1 | 0 |
| Week 24: SBP: >150 mmHg | 0 | 1 |
| Week 24: SBP: Change:>=30 mmHg decrease | 0 | 1 |
| Week 24: DBP: >90 mmHg | 1 | 1 |
| Week 24: DBP: Change>=20 mmHg decrease | 0 | 1 |
| Week 24: Pulse rate: <60 bpm | 1 | 1 |
| Week 32: DBP: >90 mmHg | 1 | 0 |
| Week 40: DBP: >90 mmHg | 1 | 0 |
| Follow-up 1: DBP: >90 mmHg | 2 | 0 |
| Follow-up 1: Pulse rate: <60 bpm | 1 | 2 |
| Follow-up 2: DBP: >90 mmHg | 2 | 0 |
| Follow-up 2: Pulse rate: <60 bpm | 1 | 2 |
Collected over Part 1, DB Period: Day 1 to Week 16; Part 1, OLE Period: Week 20 to Week 68; Part 1, DB +OLE Period: Day 1 to Week 68. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Period: Etrasimod 2 mg | 0/30 (0%) | 0/30 (0%) | 6/30 (20%) |
| DB Period: Placebo | 0/28 (0%) | 0/28 (0%) | 4/28 (14.3%) |
| OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | 0/30 (0%) | 1/30 (3.3%) | 4/30 (13.3%) |
| OLE Period: Etrasimod 2 mg (Placebo in DB Period) | 0/28 (0%) | 0/28 (0%) | 1/28 (3.6%) |
| DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | 0/30 (0%) | 1/30 (3.3%) | 9/30 (30%) |
| DB Placebo Then OLE Etrasimod 2 mg | 0/28 (0%) | 0/28 (0%) | 5/28 (17.9%) |
| Event | DB Period: Etrasimod 2 mg | DB Period: Placebo | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) | DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | DB Placebo Then OLE Etrasimod 2 mg |
|---|---|---|---|---|---|---|
| Pneumothorax spontaneousRespiratory, thoracic and mediastinal disorders | 0/30 | 0/28 | 1/30 | 0/28 | 1/30 | 0/28 |
| Event | DB Period: Etrasimod 2 mg | DB Period: Placebo | OLE Period: Etrasimod 2 mg (Etrasimod 2 mg in DB Period) | OLE Period: Etrasimod 2 mg (Placebo in DB Period) | DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | DB Placebo Then OLE Etrasimod 2 mg |
|---|---|---|---|---|---|---|
| HypertensionVascular disorders | 1/30 | 2/28 | 2/30 | 0/28 | 3/30 | 2/28 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 2/30 | 1/28 | 0/30 | 1/28 | 2/30 | 2/28 |
| COVID-19Infections and infestations | 2/30 | 0/28 | 0/30 | 0/28 | 2/30 | 0/28 |
| NasopharyngitisInfections and infestations | 2/30 | 1/28 | 0/30 | 0/28 | 2/30 | 1/28 |
| Respiratory tract infectionInfections and infestations | 0/30 | 0/28 | 2/30 | 0/28 | 2/30 | 0/28 |
The full analysis set (FAS) included all participants who were randomized to the study irrespective of whether they received any dose of study intervention (i.e., Etrasimod or placebo). Participants were analyzed in the treatment groups as they were randomized.
| Age, Continuous(Years) | DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | DB Placebo Then OLE Etrasimod 2 mg | Total |
|---|---|---|---|
| Mean | 40.0 ± 14.78 | 43.4 ± 18.18 | 41.6 ± 16.45 |
| Sex: Female, Male(Participants) | DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | DB Placebo Then OLE Etrasimod 2 mg | Total |
|---|---|---|---|
| Female | 21 | 9 | 30 |
| Male | 9 | 19 | 28 |
| Ethnicity (NIH/OMB)(Participants) | DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | DB Placebo Then OLE Etrasimod 2 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 5 | 10 |
| Not Hispanic or Latino | 25 | 23 | 48 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | DB Etrasimod 2 mg Then OLE Etrasimod 2 mg | DB Placebo Then OLE Etrasimod 2 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 24 | 27 | 51 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2023 to primary completion in Apr 2024, 15 months.
Results were first posted in May 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Etrasimod